For how we live.
The patented method uses mifepristone for hypercortisolism-related insulin resistance, with dosing capped to avoid over-activating the stress-hormone axis. The public can object before the deal closes.
Louisiana wanted mail and telehealth access to the drug shut down immediately. The judge denied that request but didn't dismiss the case either — he gave the FDA until October to finish its own review.
Relacorilant kept blood pressure under control when patients who had responded were kept on it rather than switched to placebo. The pivotal trial randomised just 62 people.